# A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

> **NCT05082285** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 724 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **COMBINATION_PRODUCT:** MenABCWY-2Gen low dose vaccine
- **COMBINATION_PRODUCT:** MenABCWY-2Gen high dose vaccine
- **COMBINATION_PRODUCT:** MenABCWY-1Gen vaccine
- **COMBINATION_PRODUCT:** MenB vaccine
- **COMBINATION_PRODUCT:** MenACWY-TT vaccine

## Key facts

- **NCT ID:** NCT05082285
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082285, "A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05082285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*